David Baker, director of the Institute for Protein Design at the University of Washington School of Medicine, is a pioneer in protein design. His contributions have been recognized with countless awards, and now, a place among the 2024 Clarivate Citation Laureates. Baker’s lab has developed several open-source software applications for nanotechnology and biomedicine. With these methods, scientists build new proteins that bind to drug targets and block them or activate cellular signals. Read More
Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) are involved in the regulation of transcription elongation, DNA damage response and genomic stability balance. A few inhibitors of CDK12- and CDK13-mediated transcription have shown antiproliferative effects in the preclinical setting but have not progressed to clinical testing due to excessive toxicity. Read More
Kronos Bio Inc. has nominated a development candidate, KB-7898, a p300 lysine acetyltransferase (KAT) inhibitor for the potential treatment of Sjögren’s disease. It is being developed as an orally available therapy for people with Sjögren’s disease, with IND-enabling studies set to begin in the fourth quarter of this year. Read More
Adcencdo ApS has obtained FDA clearance of its IND application for ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma (STS). A first-in-human phase I/II study in patients with metastatic and/or unresectable STS will recruit in the U.S. and Europe. Read More
μ-Opioid receptor agonists have been described in a Miralogx LLC patent as potentially useful for anesthesia and sedation and the treatment of anxiety disorders, asthma, depression and pain. Read More
The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe conducted machine learning and in vitro validation experiments for the identification of potential antiviral drugs effective against coronaviruses. Read More
Researchers from Nuvalent Inc. reported preclinical data of NVL-655, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors with IC50 of 0.9 and 1.8 nM against ALK wild-type (WT) and ALK G1202R/L1196M, respectively. Read More
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have jointly patented acylsulfonamide histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer. Read More
CSPC Pharmaceutical Group Ltd. has entered into an exclusive license agreement with Astrazeneca plc for the global development, manufacture and commercialization of CSPC’s lipoprotein(a) (Lp[a]) inhibitor, YS-2302018, and any pharmaceutical or biological product subsequently developed that includes the compound. Read More
Bayer Consumer Care AG has disclosed new tachykinin NK1 and NK3 receptor dual antagonists reported to be useful for the treatment of breast cancer, endometriosis, hidradenitis, hypertrichosis, osteoporosis, polycystic ovary syndrome, preeclampsia and benign prostatic hyperplasia, among others. Read More
Metastasis is the leading cause of mortality in patients with small-cell lung cancer (SCLC), with limited therapeutic options available. SCLC is characterized by a high proliferation rate, early metastasis and poor prognosis. Read More
Investigators at Nanjing Medical University and The University of Texas MD Anderson Cancer Center recently published data from their research that aimed to identify novel immunotherapy targets in triple-negative breast cancer (TNBC). Read More
Work at Dark Blue Therapeutics Ltd. has led to the identification of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a MLLT1- or MLLT3-targeting moiety through a linker. Read More
Betta Pharmaceuticals Co. Ltd. has prepared and tested probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer. Read More
In research conducted at West China Hospital of Sichuan University and Chengdu University of Traditional Chinese Medicine, coupling of the pan-FGFR inhibitor erdafitinib with a CRBN binder led to a new series of fibroblast growth factor receptor (FGFR) degraders, with compound [I] identified as the lead candidate. Read More
